Hematologist
G Papanikolaou Hospital
Vassiliki Douka, MD
Hematologist
General Hospital of Thessaloniki "George Papanikolaou"
Dr Douka Vasiliki graduated from the Department of Medical Labs from TEI Larisa in 1999 (grade Excellent) and subsequently she graduated from Medical School of Aristotle University of Thessaloniki in 2005 (grade Very Good)
She has worked as lab technician in the Cellular and Molecular Biology Lab in the Department of Hematology of the General Hospital of Thessaloniki "George Papanikolaou" in 2000-2009. In thesame hospital she completed her residence in Hematology in 2014.
Since 2014 she is responsible of the Flow Cytomotry Lab of the Department. Since 2017 she is consultant hematologist in the Department of Hematology. She is also workin in the outpatient unit of the Department treating patients of a wide spectrum of hematologic malignancies. She participates as primary investigator or subinvestigator in various clinical trials.
She has participated in various publications in international peer reviewd journals, including:
“The role of Myeloid-Derived-Stem-Cells (MDSC) in Graft-Versus-Host Disease (GVHD)” στο Journal of Clinical Medicine, “Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study” στο HemaSphere, “Extramedullary relapse and discordant CD19 expression after blinatumomab treatment” στο Current Problems in Cancer, “Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study” στο Annals of Hematology, “Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival” στο Annals of Hematology. She has additionaly participated in many posters and oral presentations in international and national conferences.
She is a memeber of the Greek Society of Hematology, of the Greek Society of Flow Cytometry, of the European Research Ιnitiative on Chronic lymphocytic leukemia (ERIC) and of the Medical Association of Thessaloniki.